SIMID First European Provider of Online Full Text Publications

SIMID is the first in Europe to use a single centralized databank to bring scientific-medical full-text publications within easy reach. Through S.M.I.L.E. (Scientific Medical Information Library Europe), medical professionals can search for and download original publications and reviews online, from prominent international peer-reviewed medical scientific journals. Currently, the database contains more than 1000 journals from 28 internationally renowned publishers. S.M.I.L.E. is accessible through www.simid.org and is made possible in part by financial institutions and companies working in the healthcare industry, such as health insurance providers and the pharmaceutical industry.

Investment by the Health Innovation Fund
Recently the Health Innovation Fund I BV has joined SIMID as an investor. This fund is financed from Achmea, OPG, ABN/AMRO and TechnoPartner (the Dutch Ministry of Economic Affairs). "We are proud that this investor has provided us the opportunity to expand our unique product further. By informing medical professionals in Europe about the latest developments within their field, our clients can help them diagnose and treat patients more adequately," comments Boudewijn Gruwel, Director of Marketing & Sales of SIMID.

How does S.M.I.L.E. work?
The medical professional has a customized subscription allowing him free access to the information in S.M.I.L.E. This customized subscription is made possible in part by companies working in the healthcare industry, or financial institutions. "The subscriptions give companies the possibility to provide medical professionals access to the most recent and relevant scientific information," states Boudewijn Gruwel.

S.M.I.L.E. lets users read the latest publications, covering 43 different themes, such as oncology, surgery, cardiology, etc. Users can compile a personal profile and receive automatic alerts when relevant articles become available. The database can also be searched using individual keywords. S.M.I.L.E. is updated daily. The publications containing the listed titles are archived from 2000 on, and all articles can be downloaded as PDF files.

Who is S.M.I.L.E.'s target audience?
The S.M.I.L.E. online database is geared toward health professionals. These might be specialists or general practitioners, but might also be dentists, nurses, or physiotherapists.

About SIMID International B.V.
SIMID stands for the Scientific Institute for Medical Information and Documentation. The goal of SIMID is to provide access to scientific-medical information for health professionals by applying the one-stop-shopping principle. Offering complete publications on a single website creates a unique niche in services to medical professionals and the international healthcare-related industry. Through cooperation with international scientific publishers and the online database S.M.I.L.E., SIMID is the first and only company in Europe able to offer this service to medical professionals. SIMID has branches in the Netherlands and Switzerland. More information can be found at www.simid.org.

About the Health Innovation Fund I BV
The Health Innovation Fund I BV is a venture capital fund established in 2007. It focuses on innovative entrepreneurs providing technological, modernizing solutions and business models for the healthcare industry. Shareholders in this fund are ABN/AMRO, Achmea and OPG. The Health Innovation Fund I BV is administered by Residex, which uses specialized investment funds to offer opportunities to promising and ambitious players in the healthcare sector. More information is available at www.residex.nl.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...